Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections
READ MORE...
Pneumagen Announces Appointment of John Beadle as Non-Executive Director
READ MORE...
Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022
READ MORE...
Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)
READ MORE...
Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections
READ MORE...
Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform
READ MORE...
Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
READ MORE...
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
READ MORE...
Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital
Website powered by 100% renewable energy